Suppr超能文献

吲哚洛尔、氯噻酮和恩屈嗪联合治疗中重度高血压的剂量探索性研究。

A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension.

作者信息

Seedat Y K, Rawat R

出版信息

S Afr Med J. 1984 Nov 3;66(18):682-4.

PMID:6387966
Abstract

This study compared the efficacy of a beta-blocker, pindolol, and a diuretic, clopamide, plus a vasodilator, endralazine, in the treatment of 30 patients suffering from moderate-to-severe hypertension. Different doses of endralazine were tested. This study showed that hypertension was controlled in 76,7% of patients receiving a combination of pindolol 10 mg and clopamide 5 mg (Viskaldix; Sandoz) plus endralazine 5 mg, and in 90% it was controlled by a combination of pindolol 10 mg, clopamide 5 mg and endralazine 10 mg daily. In 3 patients it was necessary to give pindolol 10 mg, clopamide 5 mg and endralazine 10 mg twice daily. Side-effects occurred in 5 patients, but they were not sufficiently severe for discontinuation of the therapy. There was no difference as regards the blood pressure response in the 15 Black and 15 Indian patients. Tolerance over a period of 14 weeks did not occur. Results of this study suggest that a fixed drug combination of pindolol 10 mg, clopamide 5 mg and endralazine 10 mg once daily could control blood pressure in about 90% of patients suffering from moderate-to-severe hypertension.

摘要

本研究比较了β受体阻滞剂吲哚洛尔、利尿剂氯噻酮以及血管扩张剂恩屈嗪联合治疗30例中重度高血压患者的疗效。对不同剂量的恩屈嗪进行了测试。该研究表明,接受10 mg吲哚洛尔、5 mg氯噻酮(Viskaldix;山德士公司)加5 mg恩屈嗪联合治疗的患者中,76.7%的高血压得到控制;而每日服用10 mg吲哚洛尔、5 mg氯噻酮和10 mg恩屈嗪联合治疗的患者中,90%的高血压得到控制。有3例患者需要每日两次服用10 mg吲哚洛尔、5 mg氯噻酮和10 mg恩屈嗪。5例患者出现了副作用,但严重程度不足以导致停药。15名黑人患者和15名印度患者在血压反应方面没有差异。未出现14周期间的耐受性问题。本研究结果表明,每日一次服用10 mg吲哚洛尔、5 mg氯噻酮和10 mg恩屈嗪的固定药物组合可使约90%的中重度高血压患者的血压得到控制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验